• Explore /
  • Poster
  • / A phase I study of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy.

A phase I study of ALX148, a CD47 blocker, in combination with established anticancer antibodies in patients with advanced malignancy.

Abstract Poster

Authors

null

Laura Quan Man Chow

Division of Medical Oncology, University of Washington, Seattle, WA

Laura Quan Man Chow , Justin F. Gainor , Nehal J. Lakhani , Hyun Cheol Chung , Keun-Wook Lee , Jeeyun Lee , Patricia LoRusso , Yung-Jue Bang , F. Stephen Hodi , Philip Fanning , Yonggang Zhao , Feng Jin , Hong Wan , Jaume Pons , Sophia Randolph , Wells A. Messersmith

Sign-In to See More Abstracts, Journal Articles, Posters, Videos and Slides and to Bookmark Your Favorite Content.

Disclaimer

This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org

Poster Details

Meeting

2019 ASCO Annual Meeting

Session Type

Poster Discussion Session

Session Title

Developmental Immunotherapy and Tumor Immunobiology

Track

Developmental Therapeutics—Immunotherapy

Sub Track

Immune Checkpoint Inhibitors

Clinical Trial Registration Number

NCT03013218

Citation

J Clin Oncol 37, 2019 (suppl; abstr 2514)

DOI

10.1200/JCO.2019.37.15_suppl.2514

Abstract #

2514

Poster Bd #

158

Abstract Disclosures

Similar Posters

First Author: Laura Quan Man Chow

First Author: Nehal J. Lakhani

First Author: Ruth Perets

First Author: Mohamed Shanshal